Patent · US Active

Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors

US11020431B2 · kind B2 · utility

0Cited by
0References
19Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 6, 2017
Grant dateJun 1, 2021
Priority date
Expiry dateSep 26, 2037

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2239/38
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are recombinant polynucleotides, including expression vectors encoding an alpha chain and/or a beta chain of a TCR having amino acid sequences from any of novel the AL, KQ, PP, 19305CD8, BB, KB, ST, JD, 19305DP, PB-P, PB-T, and PB 13.2 T Cell Receptors (TCRs) that are embodiments of the invention. Cells comprising the polynucleotides are provided, as are libraries of the recombinant polynucleotides and expression vectors. Methods are provided and involve administering to an individual modified human T cells that express a novel recombinant TCR. The methods are for prophylaxis and/or therapy of an individual diagnosed with, suspected of having or at risk for developing or recurrence of a cancer, wherein the cancer includes cancer cells which express NY-ESO-1 and/or its highly homologous LAGE-1 antigen.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.